NCT04177498View on ClinicalTrials.gov

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

May 5, 2025

Study Completion Date

May 5, 2025

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
DRUG

Rigosertib Sodium

given PO or 72 hour continuous infusion

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

Traws Pharma, Inc.

INDUSTRY

lead

Thomas Jefferson University

OTHER

NCT04177498 - Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC | Biotech Hunter | Biotech Hunter